CordenPharma has announced the approval of a long-term expansion initiative “to further increase our flexibility, efficiency and ultimately, cost-effective production” at its solid-phase peptide synthesis (SPPS) in Boulder, Colorado. This follows the installation of an extra-large 3,000L SPPS vessel at the site earlier this year in response to growing demand for peptide APIs.

CordenPharma is to expand non-GMP solid-phase peptide synthesis (SPPS) capacity at its centre of excellence for peptide process development and non-GMP manufacturing at Frankfurt, Germany. This should be complete in Q3 2021. The amount invested has not been disclosed.

The investment will increase lab space by 25% and add a dedicated explosionproof area. The latter will be supported by a tank farm, which, the company said, “will allow for the introduction of regular solvents, as well as compatibility with our green peptide manufacturing”.

CordenPharma has announced the addition of a 3,000-litre solid-phase peptide synthesis (SPPS) vessel at its GMP API facility in Boulder, Colorado. This site, which was formerly owned by Roche, already has a 10,000-litre SPPS vessel and a 100 cm high-pressure reverse phase purification column, and is claimed to have the largest capacity of any peptide API facility.